ライフサイエンスコーパス: veno-occlusive disease

1 17 patients (3%) had hepatic veno-occlusive disease.

2 is crucial for the development of pulmonary veno-occlusive disease.

3 transaminase and bilirubin without signs of veno-occlusive disease.

4 dysfunction, and a high frequency of hepatic veno-occlusive disease.

5 eveloped severe hepatotoxicity suggestive of veno-occlusive disease.

6 Two patients had reversible hepatic veno-occlusive disease.

7 used as therapy for Budd-Chiari syndrome and veno-occlusive disease.

8 or of 100-day mortality was the diagnosis of veno-occlusive disease.

9 acteristic that predicted the development of veno-occlusive disease.

10 al toxicities, with typical mucositis and no veno-occlusive disease.

11 imiting toxicities were observed (reversible veno-occlusive disease; 0.180 mg/kg, n=1 and 0.450 mg/kg

12 ty, any infection, organ failure, or hepatic veno-occlusive disease (1-year cumulative incidence, 71%

13 PTCY had significantly higher rates of veno-occlusive disease (14.4% vs TCRalphabeta 4.9%, P =

14 d $20,500, respectively), whereas infection, veno-occlusive disease, acute graft-versus-host disease,

15 One patient developed nonfatal veno-occlusive disease after induction II.

16 nary capillary hemangiomatosis and pulmonary veno-occlusive disease, an autosomal recessively inherit

17 Rates of veno-occlusive disease and interstitial pneumonitis were

18 in two ultra-rare subtypes of PAH, pulmonary veno-occlusive disease and pulmonary capillary haemangio

19 tioned well initially, the patient developed veno-occlusive disease and required repeat transplantati

20 irected deletion of Aplnr manifest pulmonary veno-occlusive disease and right heart failure, detectab

21 elopment of sinusoidal obstruction syndrome (veno-occlusive disease) and by total serum bilirubin lev

22 erapy; (2) posttransplant fever; (3) hepatic veno-occlusive disease; and (4) use of posttransplant gr

23 ction (presenting as the syndrome of hepatic veno-occlusive disease) are all associated with signific

24 sease, organ failure, infections, or hepatic veno-occlusive disease between groups.

25 and 3 months of age as a result of pulmonary veno-occlusive disease, capillary hemorrhage, and pancyt

26 As soon as a veno-occlusive disease diagnosis is established, treatme

27 ry by etiology, with patients with pulmonary veno-occlusive disease displaying a lack of microvascula

28 ary hypertension and differentiate pulmonary veno-occlusive disease from pulmonary arterial hypertens

29 Hepatic veno-occlusive disease (HVOD), alias sinusoidal obstruct

30 sed as a common mechanism leading to hepatic veno-occlusive disease (HVOD).

31 was also a trend toward an increased risk of veno-occlusive disease in patients with high ferritin.

32 nusoidal obstruction syndrome (also known as veno-occlusive disease) in patients during study treatme

33 Pulmonary veno-occlusive disease is caused by excessive cell proli

34 obstructive syndrome, also known as hepatic veno-occlusive disease, is a potentially life-threatenin

35 nusoidal obstruction syndrome, also known as veno-occlusive disease, is a potentially life-threatenin

36 Variation in clinical practice affects veno-occlusive disease management, mainly in patients wh

37 Veno-occlusive disease may also affect the lungs, and it

38 Veno-occlusive disease occurred twice with cyclophospham

39 No additional cases of veno-occlusive disease occurred.

40 Severe veno-occlusive disease of the liver occurred in 9 (21%)

41 Additionally, 95 patients developed veno-occlusive disease of the liver.

42 ificant acute graft-versus-host disease, and veno-occlusive disease of the liver.

43 the initiation of pulmonary vasodilators in veno-occlusive disease often leads to increased mortalit

44 otaline administration led to severe hepatic veno-occlusive disease on day 6.

45 lantation-related mortality; acute toxicity (veno-occlusive disease or acute graft versus-host diseas

46 8-5.5), GVHD (OR, 2.4; 95% CI, 1.8-3.3), and veno-occlusive disease (OR, 2.2; 95% CI, 1.4-3.6).

47 Low L-Ficolin was associated with hepatic veno-occlusive disease (P = .0053, AUC = 0.80).

48 H, drug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to c

49 4 gene (EIF2AK4) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

50 opathic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

51 athic or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

52 ients with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

53 Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonar

54 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pul

55 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pul

56 ry arterial hypertension (PAH) and pulmonary veno-occlusive disease (PVOD), respectively.

57 lungs, and it is therefore termed pulmonary veno-occlusive disease (PVOD).

58 s (n=12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17).

59 Classical veno-occlusive disease/sinusoidal obstruction syndrome (

60 en successfully used to treat severe hepatic veno-occlusive disease (sVOD) with multiorgan failure (M

61 Treosulfan causes less veno-occlusive disease than busulfan and does not requir

62 vely evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-ve

63 ary ERG and APLNR in patients with pulmonary veno-occlusive disease undergoing lung transplantation w

64 n and melphalan group had Bearman grades 1-3 veno-occlusive disease versus 21 (9%) of 239 in the carb

65 Rates of veno-occlusive disease (VOD) and thrombotic microangiopa

66 bstruction syndrome (SOS), previously called veno-occlusive disease (VOD) can be a difficult problem

67 We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and re

68 Hepatic veno-occlusive disease (VOD) is a common complication of

69 Hepatic veno-occlusive disease (VOD) is one of the most serious

70 Hepatic veno-occlusive disease (VOD) is the most common of the r

71 Veno-occlusive disease (VOD) is the most common regimen-

72 Hepatic veno-occlusive disease (VOD) is the most serious regimen

73 Veno-occlusive disease (VOD) is the third leading cause

74 One patient treated at 9 mg/m2 developed veno-occlusive disease (VOD) of the liver and defined th

75 The incidence of hepatic veno-occlusive disease (VOD) was 5% for IV-BU and 1% wit

76 Hepatic veno-occlusive disease (VOD), also called sinusoidal obs

77 ibrotide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement

78 mg/m(2) per day after recognition of hepatic veno-occlusive disease (VOD).

79 had dose limiting toxicity (DLT), including veno-occlusive disease (VOD).

80 The incidence of veno-occlusive disease was 40% (13 of 32 patients) in pl

81 The day 100 incidence of veno-occlusive disease was lower with Flu/Mel (4%) and F

82 ft failure with Flu/Mel and the high rate of veno-occlusive disease with Bu/Cy and Flu/Bu, Flu/Mel/TT

83 l recessive primary immunodeficiency disease veno-occlusive disease with immunodeficiency syndrome (V

84 ple sclerosis, chronic lymphocytic leukemia, veno-occlusive disease with immunodeficiency, as well as